Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
2.
Clinics ; 71(8): 435-439, Aug. 2016. tab
Artículo en Inglés | LILACS, SES-SP, SESSP-IDPCPROD, SES-SP | ID: lil-794635

RESUMEN

OBJECTIVE: The toxicity of anti-cancer chemotherapeutic agents can be reduced by associating these compounds, such as the anti-proliferative agent paclitaxel, with a cholesterol-rich nanoemulsion (LDE) that mimics the lipid composition of low-density lipoprotein (LDL). When injected into circulation, the LDE concentrates the carried drugs in neoplastic tissues and atherosclerotic lesions. In rabbits, atherosclerotic lesion size was reduced by 65% following LDE-paclitaxel treatment. The current study aimed to test the effectiveness of LDE-paclitaxel on inpatients with aortic atherosclerosis. METHODS: This study tested a 175 mg/m2 body surface area dose of LDE-paclitaxel (intravenous administration, 3/3 weeks for 6 cycles) in patients with aortic atherosclerosis who were aged between 69 and 86 yrs. A control group of 9 untreated patients with aortic atherosclerosis (72-83 yrs) was also observed. RESULTS: The LDE-paclitaxel treatment elicited no important clinical or laboratory toxicities. Images were acquired via multiple detector computer tomography angiography (64-slice scanner) before treatment and at 1-2 months after treatment. The images showed that the mean plaque volume in the aortic artery wall was reduced in 4 of the 8 patients, while in 3 patients it remained unchanged and in one patient it increased. In the control group, images were acquired twice with an interval of 6-8 months. None of the patients in this group exhibited a reduction in plaque volume; in contrast, the plaque volume increased in three patients and remained stable in four patients. During the study period, one death unrelated to the treatment occurred in the LDE-paclitaxel group and one death occurred in the control group. CONCLUSION: Treatment with LDE-paclitaxel was tolerated by patients with cardiovascular disease and showed the potential to reduce atherosclerotic lesion size.


Asunto(s)
Humanos , Masculino , Femenino , Anciano , Anciano de 80 o más Años , Enfermedades de la Aorta/tratamiento farmacológico , Colesterol/uso terapéutico , Paclitaxel/uso terapéutico , Aterosclerosis/tratamiento farmacológico , Moduladores de Tubulina/uso terapéutico , Nanopartículas/uso terapéutico , Aorta Torácica/efectos de los fármacos , Enfermedades de la Aorta/diagnóstico por imagen , Factores de Tiempo , Triglicéridos/sangre , Angiografía , Colesterol/sangre , Reproducibilidad de los Resultados , Resultado del Tratamiento , Sistemas de Liberación de Medicamentos , Aterosclerosis/diagnóstico por imagen , Emulsiones Grasas Intravenosas/uso terapéutico , Tomografía Computarizada Multidetector
3.
The Korean Journal of Gastroenterology ; : 172-176, 2012.
Artículo en Inglés | WPRIM | ID: wpr-47304

RESUMEN

We report herein a case of intestinal amyloidosis with grave prognosis that caused intractable diarrhea and intestinal pseudo-obstruction, alternately in spite of intensive conservative treatment. A 44-year-old woman was admitted for fever, diarrhea, and crampy abdominal pain which had been continuned during 6 months. Abdomen CT scan showed edematous wall thickening of the small bowel and right colon, and colonoscopic biopsy revealed amyloid deposition in the mucosa. Monoclonal light chains in serum and/or urine were not detected and highly elevated serum amyloid A was shown. In spite of intensive treatment including oral prednisolone and colchicine, diarrhea and intestinal pseudo-obstruction developed alternately, general status rapidly got worsened and died after two months.


Asunto(s)
Adulto , Femenino , Humanos , Administración Oral , Amiloidosis/complicaciones , Antiinflamatorios/uso terapéutico , Colchicina/uso terapéutico , Colonoscopía , Diarrea/etiología , Mucosa Intestinal/patología , Seudoobstrucción Intestinal/diagnóstico , Prednisolona/uso terapéutico , Proteína Amiloide A Sérica/metabolismo , Tomografía Computarizada por Rayos X , Moduladores de Tubulina/uso terapéutico
4.
Artículo en Inglés | IMSEAR | ID: sea-93635

RESUMEN

Behçet's disease (BD) is a multi-system inflammatory disorder which presents with recurrent orogenital ulceration, uveitis, and erythema nodosum. Medium vessel vasculitis of upper limb is extremely rare and it is only reported in patients with Behçet's disease on long follow up. Mean duration from diagnosis of disease to development of vasculitis is 5.8 years. We present a patient who presented with gangrene of fingers with absent radial pulse and during course of his illness he developed features of Behçet's disease. Diagnosis was established by clinical features and histopathology and patient was treated with steroids and colchicine.


Asunto(s)
Corticoesteroides/uso terapéutico , Arteriopatías Oclusivas/diagnóstico , Síndrome de Behçet/diagnóstico , Colchicina/uso terapéutico , Eritema Nudoso/fisiopatología , Humanos , Inflamación , Masculino , Persona de Mediana Edad , Arteria Radial/patología , Moduladores de Tubulina/uso terapéutico , Uveítis/fisiopatología , Vasculitis/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA